TCT 262: Screening selection according to the SYNTAX Score 2020 in the FASTTRACK CABG, - a First In Man study - assessing the feasibility and safety of sole MSCT guidance for CABG performance

Within the last 24 months, I have financial relationship(s) or affiliation(s) with a manufacturer, marketer, reseller, or distributor of a healthcare product or service involved in the management of patients with any cardiovascular disease to include devices, drugs, and digital health care products listed below:

• Consultant Fee/Honoraria/Speaker's Bureau (Personal) - SMT; Philips; Novartis; Merillife
• Consultant Fee/Honoraria/Speaker's Bureau (Institutional) - Xeltis